

Correction

Correction: Barak, S. et al. “Long-Term Outcomes of Early Enzyme Replacement Therapy for Mucopolysaccharidosis IV: Clinical Case Studies of Two Siblings”. *Diagnostics* 2020, 10, 108

Sharon Barak ^{1,2,*}, Yair Anikster ^{3,4,5}, Ifat Sarouk ^{6,7}, Eve Stern ⁸, Etzyona Eisenstein ¹, Tamar Yissar ¹, Nir Sherr-Lurie ⁹, Annick Raas-Rothschild ^{10,11} and Dafna Guttman ¹

¹ Department of Pediatric Rehabilitation, Edmond and Lily Safra Children’s Hospital, Chaim Sheba Medical Center, Ramat-Gan 5265601, Israel; Etzyona.Eisenstein@sheba.health.gov.il (E.E.); Tamar.Yissar@sheba.health.gov (T.Y.); Dafna.Gutman@sheba.health.gov.il (D.G.)

² Kaye Academic College of Education, M.Ed. Programs, Beer-Sheva 8414201, Israel

³ The Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel; Yair.Anikster@sheba.gov.il

⁴ Edmond and Lily Safra Children’s Hospital, Chaim Sheba Medical Center, Ramat Gan 5265601, Israel

⁵ Wohl Institute for Translational Medicine, Chaim Sheba Medical Center, Ramat Gan 5265601, Israel

⁶ The National AT Center, Chaim Sheba Medical Center, Ramat Gan 5265601, Israel; Ifat.Sarouk@sheba.gov.il

⁷ The Pediatric Pulmonology Unit, Chaim Sheba Medical Center, Edmond and Lilly Safra Children Hospital, Tel HaShomer, Ramat Gan 5265601, Israel

⁸ Pediatric Endocrine and Diabetes Unit, Chaim Sheba Medical Center, Edmond and Lily Safra Children’s Hospital, Ramat-Gan 5265601, Israel; zipporaheve.stern@sheba.health.gov.il

⁹ Pediatric Orthopedic Unit, Edmond and Lilly Safra Children Hospital, Chaim Sheba Medical Center, Ramat Gan 5265601, Israel; Nir.Sherr@sheba.health.gov.il

¹⁰ Institute of Rare Diseases, Edmond and Lily Safra Children’s hospital, Chaim Sheba Medical Center, Ramat Gan 5265601, Israel; Annick.Rothschild@sheba.health.gov.il

¹¹ The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv postcode Israel, Ramat Aviv 69978, Israel

* Correspondence: sharoni.baraki@gmail.com

Published: 14 July 2020



The authors wish to make the following correction to this paper [1]:

In the first paragraph of the Results section: “P1 and P2 started ERT with elosulfase alfa (VIMIZIM[®] by BioMarin©) 5 months post-diagnosis at age 4.5 years and 11 months, respectively, with an intravenous dose of 1.0 mg/kg/week.” The value of the dose is 1.0 mg/kg/week but should be corrected to 2.0 mg/kg/week.

These changes have no material impact on the conclusions of our paper. We apologize to our readers.

Reference

1. Barak, S.; Anikster, Y.; Sarouk, I.; Stern, E.; Eisenstein, E.; Yissar, T.; Sherr-Lurie, N.; Raas-Rothschild, A.R.; Guttman, D. Long-Term Outcomes of Early Enzyme Replacement Therapy for Mucopolysaccharidosis IV: Clinical Case Studies of Two Siblings. *Diagnostics* **2020**, *10*, 108. [[CrossRef](#)] [[PubMed](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).